Umang Vohra has been appointed an independent Non-Executive Director of Hikma Pharmaceuticals PLC. The move is tracked in our Leadership Moves tracker.

Hikma announced the appointment from London on 9 November 2026, with effect from 1 December 2026. Vohra will also be appointed a member of the Audit Committee and the Nomination and Governance Committee from the same date.

Who is Umang Vohra?

Vohra currently serves as Chair and Chief Executive Officer of Cohance Lifesciences Limited, an end-to-end innovation-led CDMO business listed in India, dividing his time between the US and India. He is also an independent board member of AGS Health, a revenue cycle management company registered in India.

His best-known role is the one before Cohance: Vohra previously served as CEO of Cipla Limited and is credited with transforming Cipla into a diversified global pharmaceutical enterprise. Earlier in his career he held senior finance, business development and operational leadership roles at Dr. Reddy’s Laboratories, including as CFO and Head of its North American business.

Why Hikma wants him

Hikma’s Chair, Victoria Hull, said it plainly in the announcement: “Umang is an experienced CEO with deep knowledge of the generic pharmaceutical market and an impressive track record in growth, innovation, portfolio development and transformation. His extensive international experience, particularly in North America, will bring valuable perspective to the Board.”

That is a precise fit, not boilerplate. Hikma is a London-listed generics and injectables company with a large US business; Vohra has run a global generics major, led a North American pharma business, and now chairs an Indian CDMO. The board is buying operating judgement in exactly the markets where Hikma earns its money.

What this signals

Indian pharma leadership is now a boardroom export. The appointment puts a Cipla-era operator on the board of a London-listed peer: for Indian executives, the signal is that a domestic CEO record — built at Cipla and Dr. Reddy’s — is now directly convertible into a London board seat. For Hikma, it is a governance hire with a practitioner’s view of generics, portfolio building and the US market.

Related reading: the other big pharma leadership move of the month — Dr Ritu Garg Takes Over as CEO, Multi Regions at Apollo Hospitals — and the month’s other headline pharma appointment — Alkem Appoints Amrut Naik as CEO.

FAQs

Who has Hikma Pharmaceuticals appointed to its board? Umang Vohra, as an independent Non-Executive Director, effective 1 December 2026.

What committees will Umang Vohra join at Hikma? The Audit Committee and the Nomination and Governance Committee, both from 1 December 2026.

What is Umang Vohra’s current role? Chair and Chief Executive Officer of Cohance Lifesciences, an end-to-end innovation-led CDMO business listed in India. He divides his time between the US and India.

Where was Umang Vohra before Cohance Lifesciences? CEO of Cipla, which he is credited with transforming into a diversified global pharmaceutical enterprise. Earlier he held senior finance, business development and operational roles at Dr. Reddy’s Laboratories, including CFO and Head of its North American business.